1. Reference

2. Berrian JL, Liu Y, Lian M, Schmaltz CL, Colditz GA. Relationship between insurance status and outcomes for patients with breast cancer in Missouri. Cancer. 2020. doi:10.1002/cncr.33330

3. Kaufman CS. ASO Author Reflections: Is Survival Sufficient? There's More to Address for the Breast Cancer Surgeon. Ann Surg Oncol. 2020. doi:10.1245/s10434-020-09350-4

4. O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, et al. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res. 2020;22(1):114. doi:10.1186/s13058-020-01349-9

5. Samuel Eziokwu A, Varella L, Lynn Kruse M, Jia X, Moore HCF, Thomas Budd G, et al. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer. Clin Breast Cancer. 2020. doi:10.1016/j.clbc.2020.09.010

6. Berg T, Jensen MB, Jakobsen EH, Al-Rawi S, Kenholm J, Andersson M. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG). Breast. 2020;54:242-7. doi:10.1016/j.breast.2020.10.014

7. Han C, Zhao F, Wan C, He Y, Chen Y. Associations between the expression of SCCA, MTA1, P16, Ki‑67 and the infection of high‑risk HPV in cervical lesions. Oncol Lett. 2020;20(1):884-92. doi: 10.3892/ol.2020.11634

8. Sant M, Bernat-Peguera A, Felip E, Margelí M. Role of ctDNA in Breast Cancer. Cancers. 2022;14(2):310. doi: 10.3390/cancers14020310

9. de Paula BHR, Kumar S, Morosini FM, Calabria Cardoso DEM, de Sousa CAM, Crocamo S. Real-world assessment of the effect of impact of tumor size on pathological complete response rates in triple negative breast cancer after neoadjuvant chemotherapy. Chin Clin Oncol. 2020.doi:10.21037/cco-20-111

10. Gui X, Li H, Yan Y, Zhang R. Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. Oncol Lett. 2020;20(6):378.doi:10.3892/ol.2020.12241

11. Dawood S, Konstantinova M, Perazzo F, Kim SB, Villarreal-Garza C, Franco SX, et al. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting. Chin Clin Oncol. 2020;9(5):61. doi.:10.21037/cco-20-138

12. Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7(1):1-13. doi:10.1038/s41523-020-00208-2

13. Hachen Jr DS. The competing risks model: A method for analyzing processes with multiple types of events. Sociological Methods & Research. 1988;17(1):21-54. doi:10.1177/0049124188017001

14. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000;18(15):2817-27. doi: 10.1200/JCO.2000.18.15.2817

15. Joulaee A, Joolaee S, Kadivar M, Hajibabaee FJInr. Living with breast cancer: Iranian women's lived experiences. 2012;59(3):362-8

16. Mokarian F, Hashemi F, Moatamedi N, Ramezani MA, Mohajeri MR, Abdeyazdan N, et al. Investigation of Prognostic Factors in Breast Cancer and their Relationship with Age and Cancer Stage. 2012;30(193)

17. Najafi B, Fakheri TJJoGUoMS. Relationship of HER-2 with other clinical–pathological diagnostic criteria in breast cancer patients. 2006;15(57):21-7

18. Moshfeghi K, Almasi Hashiani A, Motezaker JJTIJoO, Gynecology, Infertility. The relationship between HER2-overexpressing and incidence of breast cancer recurrence. 2014;17(100):10-5. doi:10.22038/ijogi.2014.2869

19. Semnani V, Farhidzadeh E, Mirmohammadkhani M, Ghahremanfard FJK. Investigation of blood levels of vitamin D in women with breast cancer and its correlation with prognostic markers. 2017:735-41.

20. Kuzhan A, Adli M, Alkis HE, Caglayan DJO. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey. J BUON. 2013; 18(3):619-22.

21. Khaled H, Salem B, Omar A-s, Omar H, Fuad S, Jerusalem PJPAJoO. Prevalence of hormonal receptors ER, PR and HER-2 NEW in breast cancer cases in Palestine. 2009;2(3):28-31

22. Khabaz MNJAPJCP. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia. Asian Pac J Cancer Prev. 2014;15(19):8395-400. dOI: 10.7314/apjcp.2014.15.19.8395

23. Effi AB, Koui BS, Koffi KD, Traore ZC, Kouyate MJAPJoCP. Breast cancer molecular subtypes defined by ER/PR and HER2 status: Association with clinicopathologic parameters in ivorian patients. Asian Pac J Cancer Prev.2016;17(4):1973-8. doi: 10.7314/apjcp.2016.17.4.1973

24. Luangxay T, Virachith S, Hando K, Vilayvong S, Xaysomphet P, Arounlangsy P, et al. Subtypes of Breast Cancer in Lao PDR: A Study in a Limited-Resource Setting. Asian Pac J Cancer Prev. 2019;20(2):589. doi: 10.31557/APJCP.2019.20.2.589

25. Sayed S, Moloo Z, Wasike R, Bird P, Oigara R, Govender D, et al. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya. Breast. 2014;23(5):591-6. doi: 10.1016/j.breast.2014.06.006

26. Yau T, Sze H, Soong IS, Hioe F, Khoo U, Lee AWJHKMJ. HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays. Hong Kong Med J. 2008, 14(2):130-5.

27. Ortiz AP, Frías O, González-Keelan C, Suárez E, Capó D, Pérez J, et al. Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast Cancer patients in Puerto Rico. P R Health Sci J. 2010;29(3):265

28. Sughayer MA, Al-Khawaja MM, Massarweh S, Al-Masri MJP, Research O. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pathol Oncol Res. 2006;12(2):83-6. doi: 10.1007/BF02893449

29. Khodabakhshi R, Reza Gohari M, Moghadamifard Z, Foadzi H, Vahabi NJRJoMS. Disease-Free Survival of Breast Cancer Patients and Identification of Related Factors. 2011;18(89)

30. Koizumi M, Yoshimoto M, Kasumi F, Iwase T. An open cohort study of bone metastasis incidence following surgery in breast cancer patients. BMC cancer. 2010;10:1-8. doi:10.1186/1471-2407-10-381

31. Lackowska B, Niezabitowski A, Rys J, Skolyszewski J, Stelmach A, Gruchala A, et al. S-phase fraction and menopausal status as the most important prognostic factors of disease-free survival for node negative patients with breast cancer. A prospective study. Pol J Pathol. 2003;54(2):101-10

32. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Loco-regional recurrence after mastectomy in high-risk breast cancer—risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol. 2006;79(2):147-55. DOI: 10.1016/j.radonc.2006.04.006

33. Rondeau V, Mathoulin-Pélissier S, Tanneau L, Sasco AJ, MacGrogan G, Debled M. Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death. BMC cancer. 2010;10:1-12. doi.:10.1186/1471-2407-10-697

34. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol. 2003;56(3):280-5. doi: 10.1016/s0895-4356(02)00614-5